Lilly’s weight loss pill orforglipron meets primary Phase III endpoint
Eli Lilly, the US market leader in the lucrative diabetes and obesity space, is now challenging its competitor Novo Nordisk in the area of oral GLP-1 receptor agonists. Lilly’s orforglipron has met the primary endpoint of its registration study and is set to be submitted for approval in the United States.